

# Pfizer Quality Improvement RFP

## Reducing Barriers to Optimal Clinical Care in Breast Cancer

Competitive Grant Program –Pfizer Internal Review Process



### Overview

This competitive program seeks to support independent quality improvement initiatives for healthcare professionals (HCPs) involved in the care & treatment of **breast cancer (BC)** patients, through the development of novel digital solutions to enhance clinical practice.

The goal is to improve the health status and quality of life of BC patients through the increased use of digitalized health care services or tools.



### Geographic Scope

Spain



### Project Types and Area of Interest

Proposed projects should be aimed at solving current healthcare delivery challenges in order to ensure that all BC patients receive optimal treatment and support. Of interest are:

- Health care gadgets, apps, websites, devices or ePRO platforms etc.
- Multi-center collaborative projects or multidisciplinary projects based on digital health care solutions.
- Collaborations between HCP and patient advocacy groups in terms of digital solutions.



### Key Milestone

- Application submission issued: March 19, 2024
- Application submission deadline: May 20, 2024
- Anticipated decision notification date: June 17, 2024
- Anticipated project start date: October 2024



### Funding Range and Project Length

Total available budget related to this RFP is approximately 200,000€.

The maximum grant amount for each project will be up to 60,000€ for initiatives with large potential reach and impact. Smaller projects are also encouraged.

Projects are encouraged to begin from October 2024 onwards, for a maximum duration of 18 months.

## I. Eligibility

---

### Geographic Scope:

- Spain

### Applicant Eligibility Criteria

- The following may apply: healthcare institutions; professional associations, medical societies, and patient advocacy groups (PAGs) involved in the assistance of BC patients.
- Only organizations are eligible to receive grants, not individuals or medical practice groups
- If the project involves multiple departments within an institution and/or between different institutions/ organizations/ associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI's grant/research coordinator).
- The Project Lead/PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. We strongly recommend that applicants confirm this with their organization or institution prior to applying. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.

## II. Requirements

---

### Date RFP Issued

- March 19, 2024

### Clinical Area

- Oncology, Breast tumors

### General Area of Interest for this RFP:

The intent of this RFP is to support independent quality improvement initiatives based on innovative digital tools or electronic care-delivery channels that will reduce barriers to optimal care of people with BC. Example issues to address might include but are not limited to management of side effects, improving frequency or efficiency of HCP/patient communications, or increasing awareness of or access to clinical trials.

Projects that will be considered for Pfizer support will focus on:

- Health gadgets, apps, websites, devices, ePRO platforms, etc. to improve the assistance of BC patients.
- Multi-center collaborative projects or multidisciplinary projects in the same center to find potential assistance gaps and address them through digital tools.
- Collaborations between healthcare professionals and patient advocacy groups in terms of digital channels.

Initiatives must propose and use digital solutions in order to digitalize clinical assistance and improve the health outcomes or quality-of-life of BC patients.

## Target Audience

- The primary audience(s) targeted for this project will be healthcare professionals focused on breast cancer (for example oncologists, specialty nurses, psychologists, pharmacists) and/or BC patients

## Expected Approximate Monetary Range of Grant Applications:

- Projects requesting up to 60,000€ per project for initiatives with large potential reach and impact will be considered. Smaller projects are also encouraged.
- The total available budget related to this RFP is approximately 200,000€.
- The grant amount to be funded will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

## Key Dates:

- RFP release date: March 19, 2024
- Grant Application due date: May 20, 2024 (Please note the deadline is 23:59 CET)
- Anticipated Grant Award Notification Date: June 17, 2024
- Grants will be distributed following a fully executed agreement. Agreements must be signed no later than September 30, 2024
- Anticipated Project Start and End Dates: from October 2024 for a maximum duration of 18 Months.

## How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled

- Please go to [www.cybergrants.com/pfizer/QI](http://www.cybergrants.com/pfizer/QI) and sign in. First-time users should click “Create your password”. *[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]*
- In the application:
  - For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)
  - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
  - Select the following Competitive Grant Program Name: **2024 ONC ES Optimal Clinical Care in Breast Cancer**
- Requirements for submission:
  - Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed.

## Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop, ([Jacqueline.Waldrop@pfizer.com](mailto:Jacqueline.Waldrop@pfizer.com)), with the subject line “Reducing Barriers to Optimal Clinical Care in Breast Cancer.”

## Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
- Payment will only be made to requesting Institution.

## Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

## Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

## About Pfizer Global Medical Grants

---

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

## Appendix

---

### General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 12-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

#### Goals and Objectives

- Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).
- List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.

#### Needs Assessment for the Project

- Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.

#### Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

#### Project Design and Methods

- Describe the planned project, the quality improvement approach, and the way the planned methods address the established need.
- If your methods include educational activities, please describe succinctly the topic(s) and format of those activities.

#### Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed.
- Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

#### Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data.
- Quantify the amount of change expected from this project in terms of your target audience.
- Describe how the project outcomes will be broadly disseminated.

## Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

## Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here

## Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

## Budget Detail

- The budget amount requested must be in Euros (EUR).
- While estimating your budget please keep the following items in mind:
  - General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
    - The inclusion of overhead costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
  - Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
  - It should be noted that grants awarded through GMG cannot be used to purchase therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.